In a large trial of the cholesterol lowering drug rosuvastatin, sold in the United States as “Crestor”, the drug was shown to reduce the risk of deep venous thrombosis (blood clots) in healthy persons by 43%. Keep in mind, however, that this trial was funded by AstraZeneca, the maker of Crestor.The significance of this trial is that statins may become a viable alternative to more traditional drug therapies used to reduce the risk of deep venous thrombosis, such as warfarin (commonly sold as “Coumadin”), which carry a significant risk of bleeding.
